Glenzocimab structure
|
Common Name | Glenzocimab | ||
---|---|---|---|---|
CAS Number | 2101829-58-5 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of GlenzocimabGlenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke[1][2]. |
Name | Glenzocimab |
---|
Description | Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke[1][2]. |
---|---|
Related Catalog | |
In Vitro | Glenzocimab (0-100000 ng/mL) 抑制 GPVI-Fc 与固定在微量滴定板上的胶原蛋白结合,IC50 为 1.37 μg/mL[2]。 |
In Vivo | Glenzocimab (1-8 mg/kg; i.v.) 抑制食蟹猴中胶原诱导的血小板聚集[2]。 Animal Model: Cynomolgus monkeys[2] Dosage: 1-8 mg/kg Administration: I.v. Result: Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus. |
References |
No Any Chemical & Physical Properties |